RELMADA THERAPEUTICS, INC. (RLMD) Form 8-K — May 12, 2026
Relmada Therapeutics reported financial results for the first quarter of 2026, posting a net loss of $19.1 million, or $0.22 per share, compared to a net loss of $17.6 million, or $0.58 per share, in the same period of 2025. The decrease in per-share loss was primarily due to an increase in the weighted average number of shares outstanding following a recent financing. Operationally, the company announced positive 12-month Phase 2 data for its lead candidate NDV-01, showing a 95% complete response rate at any time and a durable 76% complete response rate at 12 months in high-risk non-muscle invasive bladder cancer patients.
Key figures
- Eps
- -0.22
- Net Income
- -19.1 million
- Rd Expense
- 8.1 million
- Cash Position
- 234.0 million
- Shares Outstanding
- 104890223
- Ga Expense
- 11.4 million
- Cash Runway
- Through 2029
Price after filing
Close on the filing date to close N calendar days later (from $7.45). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.